- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Outpatient clinic
- Monkeypox virus
- Serum
- Pharmacological intervention
- Vaccination
- MVA-BN
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Monkeypox virus
- Blood sample
- PBMC
- Pharmacological intervention
- Vaccination
- MVA-BN
- Dryvax
- Adults (18-64 years)
- People at high risk of STIs
- STD/STI clinic
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Outpatient clinic
- Arbovirus
- Dengue virus
- Vector-borne disease
- Blood sample
- Pharmacological intervention
- Vaccination
- Qdenga
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Non-hospital health centre
- STD/STI clinic
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- HIV
- Mycoplasma genitalium
- Hepatitis
- Anorectal swab
- Oral swab
- Urethral exudate
- Pharmacological intervention
- PrEP-HIV
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Primary care
- Non-hospital health centre
- STD/STI clinic
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Pharmacological intervention
- Antivirals
- PrEP-HIV
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- PrEP users
- Hospital
- Community
- Primary care
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Pharmacological intervention
- PrEP-bSTI
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- General population
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- vasodilator
- Vericiguat
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Anti-depressant
- Tianeptine
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Plitidepsin
- Antineoplastic agent